Anticholinergic Bronchodilators - Pharmacology

SECTION 1

Historical Context & Motivation

The use of anticholinergic substances for respiratory relief predates modern pharmacology by centuries. Ancient Ayurvedic physicians burned Datura stramonium (jimsonweed) leaves and instructed patients to inhale the smoke to relieve asthmatic symptoms, unknowingly exploiting the plant's high tropane alkaloid content. These alkaloids, principally atropine and scopolamine, block muscarinic acetylcholine receptors on airway smooth muscle, thereby reducing bronchoconstriction. However, systemic absorption of these naturally occurring belladonna alkaloids produced intolerable side effects—tachycardia, xerostomia, urinary retention, and CNS disturbances—which ultimately curtailed their clinical adoption once β₂-adrenergic agonists emerged in the mid-twentieth century.

The pharmacological renaissance of anticholinergic bronchodilators began with the synthesis of quaternary ammonium derivatives of atropine. By adding a permanent positive charge to the nitrogen atom, medicinal chemists created molecules that could not readily cross lipid membranes, dramatically limiting systemic absorption after inhalation and confining pharmacological activity to the airways. This design principle gave rise to the modern inhaled anticholinergic bronchodilators that are now cornerstones in the management of chronic obstructive pulmonary disease (COPD) and, to a lesser extent, asthma.

~1800s • Belladonna Alkaloids for Asthma

Physicians in Europe and India used anticholinergic-containing plants such as Datura and Atropa belladonna in asthma cigarettes and inhalation powders, marking the earliest documented use of muscarinic antagonists for airway disease.

1920s • Isolation and Characterization of Atropine

Atropine was purified and its mechanism identified as competitive antagonism at muscarinic receptors. However, its broad systemic effects limited therapeutic utility for respiratory indications.

1975 • Ipratropium Bromide Developed

Boehringer Ingelheim synthesized ipratropium bromide, the first quaternary ammonium anticholinergic designed for inhaled delivery. Its poor systemic absorption greatly improved the safety profile over atropine.

2004 • Tiotropium Bromide Approved

Tiotropium, a long-acting muscarinic antagonist (LAMA), received approval for COPD maintenance therapy. Its kinetic selectivity for M₃ over M₂ receptors and 24-hour duration of action transformed COPD management.

2012–Present • Newer LAMAs and Combination Inhalers

Umeclidinium, glycopyrronium, and aclidinium joined the LAMA class. Fixed-dose combinations (LAMA/LABA and LAMA/LABA/ICS triple inhalers) became standard of care for moderate-to-severe COPD.

The fundamental question that drove this pharmacological evolution was: How can we selectively block parasympathetic-mediated bronchoconstriction without producing the systemic toxicity associated with atropine? The answer lay in rational drug design—modifying molecular charge and receptor subtype selectivity to target the airways while sparing the heart, GI tract, and central nervous system.

SECTION 2

Core Principles & Definitions

Anticholinergic bronchodilators achieve their therapeutic effect by antagonizing the muscarinic receptors (specifically M₃ subtype) located on airway smooth muscle and submucosal glands. Under normal physiological conditions, the vagus nerve (cranial nerve X) provides tonic parasympathetic input to the lungs, releasing acetylcholine (ACh) at postganglionic nerve terminals. When ACh binds M₃ receptors on bronchial smooth muscle, it activates the Gq–phospholipase C (PLC) signaling cascade, increasing intracellular calcium and producing smooth muscle contraction. By competitively blocking this interaction, anticholinergic bronchodilators promote smooth muscle relaxation and reduce mucus hypersecretion.

Muscarinic Receptor Subtypes

M₁ receptors facilitate parasympathetic ganglionic transmission. M₂ receptors serve as autoreceptors on prejunctional nerve terminals, inhibiting further ACh release. M₃ receptors mediate smooth muscle contraction and glandular secretion—the primary therapeutic target.

Vagal Tone & Bronchoconstriction

In COPD, resting vagal tone is the major reversible component of airway obstruction. Unlike asthma (where inflammation dominates), COPD bronchoconstriction is predominantly cholinergic, making anticholinergics especially effective in this disease.

Quaternary Ammonium Structure

All modern inhaled anticholinergics are quaternary ammonium salts. The permanent positive charge limits GI absorption (< 10% bioavailability) and prevents crossing the blood-brain barrier, thereby minimizing systemic and CNS side effects.

Kinetic Selectivity (LAMA Design)

Long-acting muscarinic antagonists like tiotropium dissociate slowly from M₃ receptors (t½ ≈ 35 hours) but rapidly from M₂ receptors (t½ ≈ 3.6 hours). This kinetic selectivity preserves M₂ autoreceptor feedback, limiting excess ACh release.

✦

KEY TAKEAWAY

Think of vagal tone as a thermostat set to 'cool' in the airways. The vagus nerve continually sends signals that keep bronchial smooth muscle partially contracted. Anticholinergic bronchodilators essentially block that thermostat signal—the smooth muscle relaxes to its baseline, opening the airway. This is analogous to disconnecting a radiator thermostat in a building: the room doesn't get colder; it simply stops being actively heated. Similarly, the airway doesn't become 'super-dilated'; it returns to its relaxed caliber.

SECTION 3

Visual Explanation: Cholinergic Pathway in the Airway

This diagram traces the parasympathetic pathway from the vagus nerve through the postganglionic terminal to M₃ receptors on bronchial smooth muscle. Note the green dashed line indicating where anticholinergic drugs (ipratropium, tiotropium) competitively block ACh at the M₃ receptor, interrupting the Gq–PLC–IP₃–Ca²⁺ cascade and preventing bronchoconstriction. The M₂ autoreceptor is shown in gold; ideal LAMAs dissociate rapidly from M₂ to preserve negative feedback on ACh release.

As the diagram illustrates, the therapeutic target is the M₃ receptor on airway smooth muscle and submucosal glands. When ACh binds M₃, the receptor couples to Gq proteins, activating phospholipase C, which cleaves PIP₂ into IP₃ and DAG. IP₃ triggers calcium release from the sarcoplasmic reticulum, driving smooth muscle contraction and mucus secretion. Anticholinergic bronchodilators compete with ACh for the orthosteric binding site on M₃, preventing this downstream signaling cascade. Importantly, the M₂ autoreceptor on the prejunctional nerve terminal normally inhibits further ACh release via a negative feedback loop. Non-selective agents that block M₂ can paradoxically increase local ACh levels, partially offsetting bronchodilation—a pharmacological nuance that drove the development of agents with kinetic selectivity for M₃ over M₂.

SECTION 4

Mechanism of Action: Receptor Pharmacology Deep Dive

Understanding anticholinergic bronchodilators requires appreciating the quantitative aspects of receptor pharmacology. The interaction between an anticholinergic drug and the muscarinic receptor follows the principles of competitive antagonism, where the drug and endogenous ACh compete for the same binding site. The degree of bronchodilation depends on the relative concentrations and binding affinities of the agonist (ACh) and antagonist (drug), as well as the receptor dissociation kinetics that determine duration of action.

Receptor Occupancy & Competitive Antagonism

DOSE RATIO (SCHILD EQUATION)

DR = 1 + [B] / K_B

DR = dose ratio (fold-shift of agonist EC₅₀ in the presence of antagonist); [B] = concentration of competitive antagonist at the receptor; K_B = equilibrium dissociation constant of the antagonist (lower K_B = higher affinity). For tiotropium at M₃, K_B is in the subnanomolar range.

RECEPTOR OCCUPANCY BY ANTAGONIST

Occupancy = [B] / ([B] + K_B)

At therapeutic inhaled doses, local airway concentrations of the antagonist [B] greatly exceed K_B, resulting in > 90% M₃ receptor occupancy, which is necessary for clinically meaningful bronchodilation.

Kinetic Selectivity: The LAMA Advantage

The concept of kinetic selectivity is central to understanding why LAMAs are preferred over non-selective muscarinic antagonists. Tiotropium, for example, has comparable thermodynamic affinity (K_B) for both M₂ and M₃ receptor subtypes. However, its dissociation half-life from M₃ is approximately 35 hours, compared to only 3.6 hours from M₂. In practical terms, tiotropium falls off the M₂ autoreceptor long before it releases from M₃, effectively restoring the negative feedback mechanism at M₂ while maintaining prolonged M₃ blockade and sustained bronchodilation.

DISSOCIATION RATE CONSTANT

t₁/₂ (dissociation) = ln 2 / k_off

t_½ = dissociation half-life; k_off = off-rate constant. A slow k_off at M₃ (long t_½) underpins once-daily dosing for LAMAs like tiotropium (35 h at M₃) and umeclidinium (≈ 22 h at M₃).

ℹ

Clinical Relevance

Blocking M₂ autoreceptors removes the brake on ACh release from postganglionic terminals. The resulting surge in local ACh can partially overcome M₃ blockade, diminishing bronchodilation. This is why older, non-selective agents like ipratropium (which blocks M₂ and M₃ equally) produce less sustained bronchodilation than kinetically selective LAMAs like tiotropium, even though ipratropium has adequate M₃ affinity.

SECTION 5

Classification of Anticholinergic Bronchodilators

Anticholinergic bronchodilators are classified primarily by their duration of action into short-acting muscarinic antagonists (SAMAs) and long-acting muscarinic antagonists (LAMAs). This classification has direct implications for clinical use: SAMAs are suited for acute symptom relief or as-needed dosing, while LAMAs serve as maintenance therapy in COPD and, increasingly, as add-on therapy in asthma. The table below summarizes the key pharmacokinetic and pharmacodynamic differences across commonly used agents.

Drug	Class	Onset	Duration	Dosing Frequency	Key Feature
Ipratropium	SAMA	15–30 min	4–6 hours	QID (4×/day)	Non-selective M₁/M₂/M₃; available as MDI and nebulizer
Tiotropium	LAMA	30 min	≥ 24 hours	Once daily	Kinetic M₃ selectivity; t½ at M₃ ≈ 35 h; Spiriva® HandiHaler or Respimat
Umeclidinium	LAMA	30 min	≥ 24 hours	Once daily	Often combined with vilanterol (LABA) in Anoro Ellipta®
Glycopyrronium	LAMA	15–30 min	12–24 hours	Once or twice daily	Fastest onset among LAMAs; Seebri Breezhaler®
Aclidinium	LAMA	30 min	12 hours	Twice daily	Rapidly hydrolyzed in plasma → minimal systemic effects; Tudorza®

Comparison of commonly used inhaled anticholinergic bronchodilators

Idealized FEV₁ improvement curves following single-dose inhalation. The orange curve (ipratropium, SAMA) peaks at 1–2 hours and declines by 6 hours, requiring four daily doses. The cyan curve (tiotropium, LAMA) maintains clinically significant bronchodilation through 24 hours, enabling once-daily dosing and better patient adherence.

The clinical significance of this pharmacokinetic difference cannot be overstated. Once-daily dosing with a LAMA dramatically improves patient adherence compared to QID dosing with ipratropium. In COPD trials, tiotropium reduces exacerbation rates by approximately 14–16% compared to placebo, an effect attributable not only to sustained bronchodilation but also to reduced mucus hypersecretion and potentially anti-inflammatory properties mediated through non-neuronal cholinergic pathways.

SECTION 6

Worked Example: Selecting Anticholinergic Therapy

The following clinical scenario demonstrates the pharmacological reasoning behind selecting an appropriate anticholinergic bronchodilator. This integrates receptor pharmacology, drug classification, and clinical guidelines.

Case: A 68-Year-Old Patient with Moderate COPD

1
Step 1 — Assess the Clinical Scenario

A 68-year-old male with a 40-pack-year smoking history presents with progressive dyspnea, chronic productive cough, and spirometry showing FEV₁/FVC ratio of 0.62 and post-bronchodilator FEV₁ of 58% predicted. He reports two exacerbations in the past year. He is currently using albuterol (SABA) PRN but remains symptomatic. Per GOLD guidelines, he is classified as GOLD Group E (moderate airflow limitation with exacerbation history).

Diagnosis: Moderate COPD, GOLD Group E — maintenance bronchodilator therapy is indicated.
2
Step 2 — Identify the Dominant Mechanism of Bronchoconstriction

In COPD, bronchoconstriction is primarily driven by increased vagal (cholinergic) tone rather than the inflammatory mediator–driven bronchospasm characteristic of asthma. The structural changes of COPD (mucous gland hyperplasia, loss of elastic recoil) are irreversible, but the cholinergic component of airway narrowing is amenable to pharmacological reversal. This makes anticholinergic bronchodilators the logical first-line maintenance choice over β₂-agonists alone, as they target the predominant reversible mechanism.

Rationale: Cholinergic tone is the primary reversible component → anticholinergic therapy is mechanistically well-suited.
3
Step 3 — Select SAMA vs. LAMA

Because this patient requires maintenance therapy (daily symptoms, exacerbation history), a LAMA is preferred over a SAMA. Ipratropium (SAMA) would require four daily doses, reducing adherence and providing inconsistent bronchodilation. A LAMA such as tiotropium or umeclidinium provides sustained ≥24-hour M₃ blockade with once-daily dosing. GOLD guidelines recommend LAMA + LABA combination as initial pharmacotherapy for Group E patients.

Selection: LAMA (tiotropium 18 μg once daily via dry powder inhaler, or umeclidinium/vilanterol combination).
4
Step 4 — Consider Combination Therapy

Given the exacerbation history (≥ 2 per year), GOLD recommends initial LAMA + LABA dual bronchodilator therapy. Umeclidinium 62.5 μg / vilanterol 25 μg (Anoro Ellipta®) delivers complementary bronchodilation: the LAMA blocks M₃-mediated cholinergic tone while the LABA activates β₂-receptors to stimulate cAMP-mediated smooth muscle relaxation. These pathways are mechanistically additive. If the patient's eosinophil count exceeds 300 cells/μL, escalation to LAMA/LABA/ICS triple therapy may be warranted.

Final plan: Umeclidinium/vilanterol (LAMA/LABA) once daily + albuterol PRN for rescue.
5
Step 5 — Anticipate Adverse Effects and Counsel

Counsel the patient about the most common anticholinergic side effects: dry mouth (xerostomia, ~10–16% of LAMA users), constipation, and urinary retention (screen for BPH). Because quaternary ammonium LAMAs have minimal systemic absorption, cardiovascular effects (tachycardia) are rare but should be monitored. Acute angle-closure glaucoma is a rare but reportable adverse effect if the drug contacts the eyes during nebulization—instruct proper inhaler technique and avoid directing the aerosol toward the face.

Key counseling points: expect mild dry mouth; report urinary difficulty; use proper inhaler technique to avoid ocular exposure.

SECTION 7

Advantages, Limitations, and Drug Comparisons

Understanding when to favor anticholinergic bronchodilators over other bronchodilator classes—and when to combine them—is essential for rational prescribing. The following comparison table highlights the strengths and weaknesses of anticholinergics relative to β₂-adrenergic agonists, the other major bronchodilator class used in obstructive airway diseases.

Parameter	Anticholinergic (LAMA)	β₂-Agonist (LABA)
Mechanism	Blocks M₃ → prevents Gq–PLC–Ca²⁺ contraction	Activates β₂ → Gs–adenylyl cyclase–↑cAMP → relaxation
Onset	Slower (15–30 min)	Faster (3–5 min for SABA; 15 min for LABA)
Best disease fit	COPD (cholinergic tone is primary reversible factor)	Asthma and COPD (addresses inflammatory mediator bronchospasm)
Tolerance / Tachyphylaxis	Minimal (no receptor downregulation)	Possible β₂ receptor desensitization with chronic use
Key adverse effects	Xerostomia, urinary retention, constipation, rare glaucoma	Tremor, tachycardia, hypokalemia, palpitations
Exacerbation reduction	Superior in COPD (tiotropium reduces exacerbations ~14–16%)	Effective, but less robust evidence for exacerbation prevention alone
Combination rationale	Additive with LABA via complementary signaling pathways	Additive with LAMA; often combined in fixed-dose inhalers

Comparative pharmacology: anticholinergic (LAMA) vs. β₂-agonist (LABA) bronchodilators

💡

CLINICAL PEARL

A key advantage of anticholinergic bronchodilators is their resistance to tachyphylaxis. Unlike β₂-agonists, which activate a stimulatory G-protein coupled pathway susceptible to receptor downregulation via GRK-mediated phosphorylation and β-arrestin internalization, muscarinic antagonists simply block a receptor without triggering downstream signaling. Since the drug does not activate the receptor, there is no stimulus for desensitization. This is analogous to placing a lock cover over a keyhole versus repeatedly inserting a key: the cover never wears the mechanism, but repeated key use gradually wears the tumblers.

SECTION 8

Connection to Advanced Respiratory Pharmacotherapy

Anticholinergic bronchodilators do not exist in therapeutic isolation. Contemporary respiratory pharmacotherapy increasingly leverages fixed-dose combination inhalers that pair a LAMA with a LABA, or even deliver triple therapy (LAMA + LABA + inhaled corticosteroid) in a single device. Understanding how anticholinergics fit into this evolving treatment landscape requires familiarity with broader pharmacological principles and emerging therapeutic strategies.

Concept	Current Understanding (This Lesson)	Advanced / Emerging Directions
Combination therapy	LAMA/LABA dual bronchodilators provide additive bronchodilation via complementary pathways	Triple therapy (LAMA/LABA/ICS) in single inhalers (e.g., fluticasone furoate/umeclidinium/vilanterol) reduces exacerbations and mortality in COPD; quadruple therapy trials underway
Receptor pharmacology	Kinetic selectivity (slow M₃ dissociation, fast M₂ dissociation) governs LAMA design	Bifunctional muscarinic antagonist/β₂-agonist (MABA) molecules under development — single compounds with dual mechanisms (e.g., batefenterol)
Non-neuronal ACh	Focus on vagal nerve–derived ACh acting on smooth muscle M₃ receptors	Epithelial cells, macrophages, and lymphocytes express non-neuronal cholinergic systems. LAMAs may modulate airway inflammation and remodeling via these pathways
LAMA in asthma	Anticholinergics are primarily COPD drugs; ipratropium used adjunctively in acute severe asthma	GINA 2023 recommends add-on tiotropium (Respimat) for patients with uncontrolled asthma on Step 4/5 therapy (medium–high dose ICS/LABA)
Pharmacogenomics	Uniform dosing of LAMAs based on disease severity	CHRM3 gene polymorphisms may influence M₃ receptor expression and drug response; precision medicine approaches are being explored

Current foundations vs. emerging directions in anticholinergic bronchodilator therapy

As research advances, the line between bronchodilators and anti-inflammatory agents continues to blur. The discovery that non-neuronal cholinergic signaling participates in airway inflammation, mucus cell metaplasia, and fibroblast proliferation suggests that LAMAs may offer disease-modifying effects beyond simple symptom relief. Future pharmacotherapy may increasingly leverage bifunctional molecules that combine muscarinic antagonism with β₂-agonism or even anti-inflammatory activity in a single pharmacophore, simplifying treatment regimens and potentially improving outcomes.

SECTION 9

Practice Problems

Question 1: CONCEPTUAL

Explain why anticholinergic bronchodilators are generally more effective in COPD than in asthma. In your answer, identify the predominant mechanism of reversible bronchoconstriction in each disease.

Show answer

In COPD, the primary reversible component of airway obstruction is increased vagal (parasympathetic) cholinergic tone. The vagus nerve releases ACh, which binds M₃ receptors on bronchial smooth muscle, causing contraction. Anticholinergics directly antagonize this mechanism. In asthma, bronchoconstriction is driven predominantly by inflammatory mediators (histamine, leukotrienes, prostaglandins) that contract smooth muscle through non-cholinergic pathways. While vagal reflexes contribute to asthmatic bronchospasm, they are not the dominant mechanism. Therefore, anticholinergics address the central reversible pathway in COPD but only a secondary pathway in asthma, making them more effective in the former disease.

Question 2: BASIC CALCULATION

Tiotropium has a dissociation half-life (t₁/₂) of approximately 35 hours at the M₃ receptor. Using the relationship t₁/₂ = ln 2 / k_off, calculate the off-rate constant (k_off) for tiotropium at M₃. Express your answer in h⁻¹.

Show answer

Rearranging the equation: k_off = ln 2 / t₁/₂ = 0.693 / 35 h ≈ 0.0198 h⁻¹. This extremely slow off-rate (approximately 0.02 per hour) means that at any given hour, only about 2% of bound tiotropium molecules dissociate from M₃ receptors. This slow dissociation is what enables once-daily dosing: even 24 hours after inhalation, a substantial fraction of M₃ receptors remain occupied by the drug, maintaining bronchodilation. By contrast, ipratropium's faster k_off requires dosing every 4–6 hours.

Question 3: INTERMEDIATE

A patient on tiotropium monotherapy continues to experience frequent COPD exacerbations and daily symptoms. Using your understanding of bronchodilator pharmacology, explain the mechanistic rationale for adding a LABA (e.g., vilanterol) rather than switching to a higher dose of tiotropium.

Show answer

At standard inhaled doses, tiotropium already achieves > 90% M₃ receptor occupancy in the airways. Increasing the dose would provide minimal additional bronchodilation due to the ceiling effect of receptor saturation, while potentially increasing systemic side effects. Adding a LABA such as vilanterol introduces a mechanistically complementary pathway: β₂-receptor activation stimulates Gs-coupled adenylyl cyclase, increasing intracellular cAMP, which activates protein kinase A and leads to smooth muscle relaxation via phosphorylation of myosin light chain kinase. This cAMP-mediated relaxation is additive with the reduction in intracellular calcium achieved by M₃ blockade. The two drugs act through independent signaling cascades (Gq blockade via LAMA + Gs stimulation via LABA), producing greater bronchodilation than either agent alone at maximal doses.

Question 4: APPLIED

A 72-year-old male with COPD and benign prostatic hyperplasia (BPH) is started on tiotropium. Two weeks later, he presents with acute urinary retention. Explain the pharmacological basis for this adverse effect, why it is more likely in patients with BPH, and propose an alternative anticholinergic agent or management strategy.

Show answer

Although tiotropium is designed for topical airway delivery with minimal systemic absorption (< 5% oral bioavailability for the swallowed portion), small amounts can reach the systemic circulation. M₃ receptors on the detrusor muscle of the bladder mediate contraction during micturition. Systemic antimuscarinic activity, even at low levels, reduces detrusor contractility. In a patient with BPH, the prostate already mechanically obstructs the urethra, and detrusor function is often already compromised. The additive effect of even minimal M₃ blockade in the bladder can precipitate acute urinary retention. Alternatives include switching to aclidinium, which is rapidly hydrolyzed by plasma esterases (minimizing systemic exposure), or using the Respimat soft-mist inhaler formulation of tiotropium (lower delivered dose, 2.5 μg vs. 18 μg HandiHaler). The patient should also be referred to urology for BPH management, and the clinical team should weigh the respiratory benefits against urological risk.

Question 5: CRITICAL THINKING

Tiotropium is described as having 'kinetic selectivity' for M₃ over M₂, despite having similar thermodynamic affinity (

K_B

) for both receptor subtypes. Critically analyze why kinetic selectivity—rather than thermodynamic selectivity—is the pharmacologically relevant property. Consider what would happen if a drug had high thermodynamic affinity for M₃ but blocked M₂ equally at steady state, and how this would affect bronchodilation.

Show answer

Thermodynamic affinity (

K_B

) describes the equilibrium binding constant and indicates how tightly a drug binds when the system reaches equilibrium. However, in vivo, receptor occupancy is governed by kinetics—the rates of drug association (k_on) and dissociation (k_off). Tiotropium's

K_B

values at M₂ and M₃ are comparable, meaning at equilibrium, occupancy of both subtypes would be similar. However, tiotropium dissociates from M₃ with a t₁/₂ of ~35 hours but from M₂ with a t₁/₂ of only ~3.6 hours. This means that within the 24-hour dosing interval, M₂ receptors become unblocked while M₃ receptors remain occupied. The functional consequence is critical: M₂ autoreceptors on postganglionic nerve terminals resume their negative feedback function, inhibiting excess ACh release. If M₂ were persistently blocked, the loss of this autoinhibitory brake would increase ACh release at the neuroeffector junction, and the elevated ACh would compete with the drug for M₃ binding, potentially reducing net bronchodilation. Therefore, a drug with equal steady-state occupancy at M₂ and M₃ would be self-defeating—it would simultaneously block the therapeutic target (M₃) and remove the endogenous mechanism that limits agonist competition at that target (M₂ autoreceptor). Kinetic selectivity elegantly resolves this pharmacological dilemma by allowing temporal dissociation of receptor subtype blockade.

SUMMARY

Anticholinergic Bronchodilators — Summary

Summary

Anticholinergic bronchodilators work by competitively blocking M₃ muscarinic receptors on airway smooth muscle and submucosal glands, preventing the Gq–PLC–IP₃–Ca²⁺ signaling cascade that mediates vagally driven bronchoconstriction and mucus secretion. Modern agents are quaternary ammonium salts with minimal systemic absorption, designed for inhaled delivery. They are classified as SAMAs (ipratropium, 4–6 hour duration, QID dosing) or LAMAs (tiotropium, umeclidinium, glycopyrronium, aclidinium; ≥12–24 hour duration, once- or twice-daily dosing).

LAMAs exhibit kinetic selectivity for M₃ over M₂ autoreceptors, preserving negative feedback on ACh release while maintaining prolonged M₃ blockade. They are first-line maintenance therapy in COPD (where cholinergic tone is the primary reversible component of obstruction) and are frequently combined with LABAs for additive bronchodilation via complementary signaling cascades. Key adverse effects include xerostomia, urinary retention (caution in BPH), constipation, and rare acute angle-closure glaucoma. Unlike β₂-agonists, anticholinergics show minimal tachyphylaxis because they block rather than activate their target receptor, avoiding desensitization.